The Norwegian biotech company has announced the appointment of Namir Hassan as chief scientific officer (CSO). “Namir has gathered extensive scientific knowledge in immunology, and, specifically, T-cell receptor based therapies. His experience spans research through to translational developmentAlready a subscriber Login You have read all your free articles, to continue…